| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10040202 | HBV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS10040086 | HBV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS30010849 | HIV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS20037373 | HPV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS20039601 | HPV | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
| TVIS44012431 | HTLV-1 | ENSG00000157404.17 | protein_coding | KIT | Yes | No | 3815 | P10721 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | KIT |
|---|---|
| DrugBank ID | DB11800 |
| Drug Name | Tivozanib |
| Target ID | BE0000453 |
| UniProt ID | P10721 |
| Regulation Type | inhibitor |
| PubMed IDs | 33101775; 31496820 |
| Citations | Kalathil SG, Wang K, Hutson A, Iyer R, Thanavala Y: Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients. Oncoimmunology. 2020 Sep 30;9(1):1824863. doi: 10.1080/2162402X.2020.1824863.@@Yalcin S, Lacin S: Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma. Cancer Manag Res. 2019 Aug 16;11:7779-7785. doi: 10.2147/CMAR.S206105. eCollection 2019. |
| Groups | Approved; Investigational |
| Direct Classification | Diarylethers |
| SMILES | COC1=C(OC)C=C2C(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=CC=NC2=C1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL1289494 |
